Pharmacy Track
 

The IDN pharmacy supply chain plays a vital role in patient outcomes. Hospital pharmacy executives continue to look for innovative methods of improving quality while keeping costs low. However, the problems facing the pharmacy segment of healthcare are complex. This track will outline action plans for you to prepare for 2020, including using data effectively, pricing transparency, distribution models, rule changes impacting reimbursements, and more.

Monday, September 9, 2019
1:00 PM - 2:15 PM
Grand Saguaro East

Moderator: Bonnie Kirschenbaum,  Consultant, Columnist

Presenter: Joshua Soliman, Associate Director, Pharmacy Operations and Transformation, NYU Langone Health System

IDN pharmacies and pharmaceutical manufacturers handle massive amounts of data, including information about scripts, prescribers, insurance companies and patients. Navigating that data, and figuring out how to use it most efficiently, is challenging. Patient outcomes and improved efficiencies of pharmacy operations certainly prove that figuring out data aggregation and data analytics are worth the challenge.

We’ll begin this session with a presentation of a strategic overview of the challenges IDN pharmacy face as you drive better outcomes with increased aggregation and analytics. Next, we’ll discuss how to aggregate infusion pump data in conjunction with data from other technologies like the EHR and dispensing cabinets, to identify drug waste based on how drugs are being ordered, prepared and dispensed versus how they are actually being administered to the patient.

Learning Objectives:
1) Assemble patient data in meaningful and manageable ways to improve patient outcomes.
2) Demonstrate how manipulating data from multiple sources can improve efficiencies in IDN pharmacy operations.
3) Translate data from multiple sources to positively impact drug shortage situations.

 

View Presentation

Moderator
Bonnie Kirschenbaum MS, FASHP, FCSHP
Consultant,  Columnist,  Freelance
Presenter
Joshua Soliman
Assistant Director, Pharmacy Operations, NYU Langone Health
Monday, September 9, 2019
2:30 PM - 3:45 PM
Grand Saguaro East

Moderator: Bonnie Kirschenbaum, Consultant and Columnist

Panelists: Allen Broome, Assistant VP Pharmacy Services, Erlanger Health System and Melissa Duke, Senior Director, Ambulatory Pharmacy Services, Banner Health

It is imperative to stay focused on strategic, longer range initiatives as you lead your IDN pharmacy operations. Some of these issues that will continue to have impact are: buy and bill versus incorporating specialty pharmacy decisions; how are your reviewing new models that incorporate more partnerships with payors as well as the manufactures; managing more varied locations and working with the patient mix for each location; protecting against illicit drug use including more regulations on opioids; among many other topics we’ll explore in this strategic discussion on IDN pharmacy operations. 

Learning Objectives:

1. Compare different issues impacting IDN pharmacies and decide where you need to focus.

2. Assemble information on issues that you believe will impact your operations in 2020.

3. Describe the impact of non-action if your IDN doesn’t react to upcoming events. 

 

View Presentation

Moderator
Bonnie Kirschenbaum MS, FASHP, FCSHP
Consultant,  Columnist,  Freelance
Panelists
Melissa Duke
Senior Director,  Ambulatory Pharmacy Services, Banner Health
Allen Broome 
Assistant VP, Pharmacy Services, Erlanger Health System
Monday, September 9, 2019
4:00 PM - 5:15 PM
Grand Saguaro East

Moderator: Lisa Ponssa, EVP, Healthcare Business Media 

Presenters: Bonnie Kirschenbaum, Consultant and Columnist and Steven Schnelle, Associate, McDermott, Will & Emery

After years of public outrage, an increasing wave of proposals addressing drug pricing have emerged at both the state and the national levels throughout 2019. While the end goal is to lower the costs for payor, provider and patient through greater pricing transparency and more efficient distribution models, these complex proposed changes will have far reaching implications for in and out patient hospital operations. 

This session first will dive into the pricing proposals in play and include discussions of the Prescription Drug Pricing Reduction Act of 2019 and The Safe Importation Action Plan among others. A discussion of the implications of proposed 2020 OPPS and PFS payment rules (among others) then follows. The proposed rules also have taken a strong stance on transparency as well as clearly defining reimbursement strategy in a site neutral manner. There won't be any margins to manage without an understanding of the rule sets and changes in strategy! 

Learning Objectives:   

1. Define the potential impact new pricing proposals and rules have on Medicare, Medicaid reimbursement for hospital pharmacy operations.

2. Differentiate the components of the various proposals and rules impacting IDN pharmacy operations.

3. Analyze the importance of IDN specific analytics when preparing for these proposals and rules that will impact your pharmacy supply chain.

 

View Presentation

Moderator
Lisa Ponssa
EVP 
Healthcare Business Media
Presenter
Bonnie Kirschenbaum MS, FASHP, FCSHP
Consultant,  Columnist,  Freelance
Steven Schnelle
Associate, McDermott, Will & Emery